Morningstar

Roche Holding AG Ordinary Shares new ROP

Morningstar Rating
Unlock
Stock XSWX Rating as of
CHF 336.60 +1.10 (0.33%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Roche Branded Drug and Diagnostics Arms Support a Steady Wide Moat

Karen Andersen

We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare giant is in a unique position to guide global health care into a safer, more personalized, and more cost-effective endeavor. Strong information sharing continues between Genentech and Roche researchers, boosting research and development productivity and personalized medicine offerings that take advantage of Roche's diagnostic expertise and artificial intelligence leadership.

Read Full Report

Price vs Fair Value

View History
ROP is trading at a LOCK|Hq@jlg^ premium.
Price
CHF 336.60
Fair Value
<WG
Uncertainty
LOCK|gl
1-Star Price
LOCK|!.XM
5-Star Price
LOCK|Q.^
Economic Moat
LOCK|F^#
Capital Allocation
LOCK|?$j!Kf&

Bulls Say, Bears Say

Bulls

Roche and its innovative US arm Genentech have a solid history of generating blockbuster therapies in oncology, and Roche's pipeline is full of novel candidates, with a particularly large late-stage pipeline.

Bears

Roche's immuno-oncology drug Tecentriq was launched third to market behind Bristol's Opdivo and Merck's Keytruda, raising questions about Roche's innovation.

Show More

News

View All

Trading Information

Previous Close Price
CHF 335.50
Day Range
CHF 335.20–340.30
52-Week Range
CHF 243.90–374.90
Bid/Ask
CHF 0.00 / CHF 340.00
Shares Outstanding
795.62M
Market Cap
CHF 267.80B
Volume/Avg
996,548 / 980,163

Key Statistics

Price/Earnings (Normalized)
15.83
Price/Sales
4.24
Dividend Yield (Trailing)
2.91%
Dividend Yield (Forward)
2.91%
Total Yield
2.91%

Company Profile

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Core
Total Number of Employees
112,774
Website
https://www.roche.com

Competitors

Valuation

View More
Metric
ROP
ABBV
REGN
Price/Earnings (Normalized)
 15.8324.9914.82
Price/Book Value
 7.88—2.26
Price/Sales
 4.247.194.88
Price/Cash Flow
 13.9219.7015.93
Price/Earnings
ROP
ABBV
REGN

Financial Strength

Metric
ROP
ABBV
REGN
Quick Ratio
 1.100.522.84
Current Ratio
 1.380.803.57
Interest Coverage
 13.462.9693.30
Quick Ratio
ROP
ABBV
REGN

Profitability

Metric
ROP
ABBV
REGN
Return on Assets (Normalized)
 15.77%13.37%12.66%
Return on Equity (Normalized)
 49.73%—16.34%
Return on Invested Capital (Normalized)
 23.68%29.17%13.26%
Return on Assets
ROP
ABBV
REGN

Drug Manufacturers - General Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Eli Lilly and Co
LLY
LOCK|VC&@%&&fLOCK|sGm$1T
 Johnson & Johnson
JNJ
LOCK|!!Lp^^LOCK|&>$619B
 AbbVie Inc
ABBV
LOCK|<<@QKLDLOCK|Dq$438B
 Roche Holding AG ADR
RHHBY
LOCK|@<%<vjp!LOCK|wp$333B
 Merck & Co Inc
MRK
LOCK|pnMVqDLOCK|^<m$305B
 Novartis AG ADR
NVS
LOCK|F!%WbNg?LOCK|>>$294B
 AstraZeneca PLC
AZN
LOCK|n%YMq^&ZLOCK|R$$267B
 Novo Nordisk AS ADR
NVO
LOCK|<#y<n#!LOCK|r$$$218B
 Amgen Inc
AMGN
LOCK|rf$<%hK<LOCK|CD$196B
 Gilead Sciences Inc
GILD
LOCK|!ngVM?LOCK|b<$161B

Sponsor Center